Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines using chromosome 11 specific probes showed deletion and translocation of 11q13 sequences in five out of eight cell lines. Fluorescence in situ hybridization (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 sequences in the HeLa cells. In order to determine whether 11q13 deletions occur in primary cervical tumors, we analysed 36 tumors using 20 different microsatellite and RFLP markers. Semi automated fluorescein based allelotyping was performed to identify loss of heterozygosity (LOH) in tumors. The results showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near MEN1, the second near D11S913, and the third near INT2 locus were observed. The smallest region of deletion overlap at the D11S913 locus was localized to a 300 Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) probes, confirmed allelic deletion in the tumors. PCR analysis further identified homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore that a putative cervical cancer tumor suppressor gene exists within the 300 kb of chromosome 11q13.
Introduction
Cervical cancer is one of the leading causes of female death worldwide with 500 000 deaths reported each year. Recent cancer statistics shows that in the US 4900 women die of cervical cancer every year (Landis et al., 1998) . It is the third cause of death from cancer in women of 15 to 34 years of age and the fifth leading cause of death in women of 35 to 54 years, representing about 2% of all cancers in women in the US.
Human papilloma viruses (HPV) are detected in 90% of cervical cancers and the viral genome is expressed in the tumor (Zur Hausen, 1991) . HPV is also found to play an important role in the development of cervical tumors from precursor lesions (Liaw et al., 1999) . Of the over 82 completely sequenced genotypes of HPV, only a handful (predominantly HPV 16, 18 and 31) are associated with invasive cancers (Stoler et al., 1992) . These invasive tumors develop from precursor lesions termed cervical dysplasia (cervical intraepithelial neoplasia); but not all dysplasia develop into cancers.
HPV infection may not be sufficient for tumor development. Genetic alterations such as activation of oncogenes and inactivation of tumor suppressor genes may be involved. There have been few reports implicating oncogenes c-MYC and HRAS1 in cervical cancers (Ocadiz et al., 1987; Riou et al., 1988) . These studies showed activation of these oncogenes only in a subset of cervical cancers and in association with advanced stage of the disease. Thus, tumor suppressor genes are considered to play an important role in the development of cervical cancer.
Chromosomal deletions representing the location of tumor suppressor genes can be identified by cytogenetic and molecular genetic analysis of tumor samples. Cytogenetic studies of primary cervical tumors have shown non-random structural changes involving chromosomes 1, 4 or 5, 11 and 17 (Sreekantaiah et al., 1987; Atkin et al., 1990) . Comparative genomic hybridization (CGH) of cervical tumors has identified over-representation of chromosome 3q as a recurrent event in invasive tumors and additional genetic aberrations including under-representation of chromosomal arms 2q, 3p, 6q, 8p, 10q, 11q and 13q in progression from invasive to advanced stage tumors (Heselmeyer et al., 1996 (Heselmeyer et al., , 1997 Allen et al., 2000) . Chromosome 11 painting, spectral karyotyping and comparative genomic hybridization (CGH) studies have shown rearrangement of chromosome 11q13 sequences in the HeLa cells (Macville et al., 1999) . FISH studies have also revealed the presence of a 2.3 Mb interstitial deletion in the HeLa cell line D98/ AH-2 (Srivatsan et al., 2000) . While gain of 3q may represent the presence of an oncogene at this locus, the chromosomal losses could represent the location of tumor suppressor genes.
Loss of heterozygosity (LOH) studies of primary tumors shows allelic loss on various chromosomal arms (Mitra et al., 1994; Mullokandov et al., 1996) . The common region of allelic loss in these tumors is on chromosomes 3p, 6p, 11q and 18q. Of these, deletions on 3p and 11q have been confirmed by LOH studies using chromosome specific probes (Srivatsan et al., 1991; Hampton et al., 1994; Guo et al., 1998; Pulido et al., 2000) . Studies by Pulido et al. (2000) have also localized the allelic loss to a 6-cM interval at chromosome 11q23.
Functional studies, involving suppression of tumorigenic phenotype using single chromosome transfers into cervical cancer cell lines, confirmed the presence of a tumor suppressor gene on chromosome 11 (Saxon et al., 1986; Koi et al., 1989) . Molecular genetic analysis of tumorigenic and non-tumorigenic hybrids, derived from chromosome transfer experiments, localized the gene to the long arm of chromosome 11 (Misra and Srivatsan, 1989) . The gene was sub-localized to 11q13 by the presence of 11q13 specific deletions and translocations in five of eight cervical cancer cell lines (Jesudasan et al., 1994 (Jesudasan et al., , 1995 Horikawa et al., 1995) . Thus, to verify whether a cervical cancer tumor suppressor gene may be localized to chromosome 11q13, we investigated primary tumors for deletion of 11q13 sequences. Thirty-six tumors were analysed using 20 different microsatellite and RFLP markers. FISH was performed on tumor touch preparations with cosmid and BAC probes to verify the deletion data. Here we show that 11q13 sequences are deleted in a significant fraction of primary cervical cancers. We also show that a 5.7 kb interval of 11q13 sequences is homozygously deleted in the HeLa cells and in two different HeLa cell derived tumorigenic hybrid cell lines.
Results

Deletion of 11q13 sequences in primary tumors
Thirty-six cervical tumors and the corresponding normal tissue DNAs were analysed using 20 different 11q13 specific probes (Figure 1a) . Nineteen of the markers are localized to the 5.6 Mb interval between markers PYGM and INT2 and the marker D11S533 is localized 8 Mb distal to INT2, thus spanning a total distance of 13.6 Mb for the 20 probes (Courseaux et al., 1996; Wood et al., 1996; Guru et al., 1997) . While only two probes were informative in sample 1, multiple probes exhibited polymorphic alleles in all other tumor samples. The results were confirmed by at least three independent PCR and microsatellite analyses.
Seventeen tumors showed allelic loss for the 11q13 probes (Figure 2 ). Deletion of greater than 50% for an allele was observed in fourteen samples. The remaining three samples (tumors 4, 22, and 34) had a greater than 30% loss for the deleted allele. Three tumors (samples 4, 5 and 15) lost an allele for all the informative markers indicating possible deletion of the entire chromosome or at-least the long arm. Of the remaining 14 tumors, proximal 11q13 was lost in samples 1 and 16, interstitial deletion was seen in twelve tumors (Figure 2) .
Tumor 3 lost an allele for D11S4936 while retaining heterozygosity for proximal probes PYGM and 137C7A (Figure 3a ) and the various distal probes (Figure 2 ). Tumors 7, 18 and 34 showed loss of an allele near the MEN1 locus and at a distal site. The distal deletion in tumor 18 was localized between D11S4907 and INT2. The boundaries of deletion in tumor 20, containing an interstitial deletion, were between PYGM and D11S533. Interstitial deletion in tumor 21 was localized between 137C7A and D11S5023 (Figures 2 and 3b) . Tumor 29 showed allelic loss for probes between D11S4936 and D11S987 (Figures 2 and 3c) . The proximal and distal boundaries of deletion at the D11S913 locus in tumor 34 were D11S4908 and CTTT respectively (Figure 3d ). Finally, loss of INT2 locus was observed in tumors 4, 14, 22, 23, 24, 30 and 32 . Thus, the data from the above tumors revealed three different sites of allelic deletion, one near MEN1, the second near D11S913, and the third near INT2. The smallest region of deletion overlap at the D11S913 site was localized to a 300 kb interval between D11S4908 and D11S5023, the proximal and distal breakpoints in tumors 34 and 21 respectively (Figure 2 ).
Confirmation of 11q13 loss using FISH
To verify the LOH data, FISH was performed on nine tumor touch preparations, using chromosome 11 centromeric and 11q13 specific cosmid and BAC probes. While five locus specific probes were used for the analysis of all nine tumors, four additional probes were used for tumors 3, 7, and 18, that showed deletions both at MEN1 and at a distal locus. Tumors 6 and 15 were also studied with an additional PYGM probe. Two tumors (5 and 16) contained three and the The distances between markers were derived by contig mapping studies (Wood et al., 1996; Courseaux et al., 1996; Guru et al., 1997) . A distance of 1.5 Mb separates D11S913 and GSTP1. While red and blue represent FISH probes present in the normal appearing chromosome 11 copies of D98/AH-2 cells, green refers to probes (41I21, 92C11, 149A4 and 152L21) deleted from the der(3) marker chromosome of D98/AH-2. However, these probes are present and are duplicated in the der(11) marker chromosome of the other HeLa cell line, CCL2. (b) Restriction map of the BACs was obtained by Southern blot hybridization of the partial restriction fragments using the STS markers, localized between D11S4908 and 776E2R, and the BAC end clones as probes. (c) Location of the restriction enzymes sites and that of the ESTs were derived from the genomic sequence of 152L21 BAC DNA and the PCR primers were designed using the Primer 3 program. Homozygous deletion refers to the deletion observed in HeLa cells and in the HeLa cell derived tumorigenic hybrid cell lines. TSG refers to putative tumor suppressor gene localized between D11S4908 and D11S5023. Map is not drawn to scale . This tumor has retained heterozygous alleles for D11S4908 and CTTT. These results localize a minimal deletion between D11S4908 (seen in tumor 34) and D11S5023 (seen in tumor 21), a distance of 300 kb. Arrows point to the deleted allele. Numbers at the bottom refer to the ratio of larger to shorter allele rest two copies of the centromeric probe (Table 1) . Locus specific probes showed allelic loss in eight of the tumors including tumor 6 that was used as the deletion free sample based on microsatellite analysis.
FISH analysis confirmed the existence of a deletion, distal to MEN1, in cervical cancer. Tumors 1, 6 and 16 showed deletion of proximal probes and the retention of INT2 containing cosmid 25G9 localizing the distal break point to INT2. Interestingly, partial loss of the Oncor cocktail INT2 probe (a 100 kb cocktail mixture) was observed in these tumors. This is likely due to the deletion of the proximal region of INT2 cocktail probe and the retention of the distal region represented by cosmid 25G9 in the tumor cells. Taken together the results refine the distal boundary of deletion to the 100 kb sequence of the INT2 locus.
Although the microsatellite analysis did not reveal loss of D11S913 locus in tumor 3 (Figure 2 ), the FISH data showed deletion of MEN1 probe c10B11 as well as probes 41I21 and 152I21 or D11S913 locus. Retention of probes c25G9, c32D10, c102C11, b184C17, b57D24 in this tumor and in tumor 18 indicated deletion of both the MEN1 and the D11S913 loci in these tumors. Thus the deletion at D11S913 was mapped distal to D11S546 (c102C11), the same as was seen with the microsatellite analysis. A representative example of the loss of a c10B11 copy in tumor 3 is shown in Figure 4a . Two copies of all six probes were seen in tumor 15 (Figure 4b ). With the presence of two centromeric copies and loss of all informative microsatellite markers in this tumor (Table 1 and Figure 2 ), the data suggested isodisomy with complete loss of the second homolog of chromosome 11 in tumor 15.
Finally, FISH showed deletion of a copy of c88G7, c10B11, b41I21 and b152L21 probes in tumor 6 ( Figure 4c ) and the retention of INT2 probes ( Figure  4d ). The microsatellite analysis, however, did not identify allelic loss in this sample (Figure 2 ). Since H&E staining has shown greater than 70% of tumor cells in most of the tumor samples (data shown), the FISH data suggested that the deletion might represent a sub-clonal loss of 11q13 sequences in tumor 6.
Higher fraction of constitutional cell contamination could also result in a failure to detect allelic deletion by the microsatellite analysis. Again as in tumor 3, FISH detected deletions of D11S913 locus in additional tumor samples not seen by the microsatellite analysis.
Homozygous deletion of D11S913 sequences in a primary tumor
The PCR analysis, with the 11q13 markers, revealed absence of a product for the D11S913 probe in tumor 12, indicating the homozygous loss of the probe sequences in this tumor ( Figure 5 ). All other markers including those yielding larger PCR products (e.g. INT2 probe with a product size of 745 bp) were present in the tumor sample (Figure 2) . Products for the T7 and SP6 ends of BAC152L21 were present in the tumor, localizing the deletion to the 75 kb interval of the BAC end sequences. High frequency of repetitive sequences near D11S913, coupled with the limited availability of the tumor sample precluded additional studies to narrow the region of homozygous deletion.
Homozygous deletion in HeLa cells and in HeLa cell derived tumorigenic hybrid cell lines
Various HeLa cell isolates are described in the literature. Two common isolates are D98/AH-2 used in cell fusion studies (Stanbridge, 1976) and CCL2 used in CGH and spectral karyotyping analysis (Macville et al., 1999) . Both cell lines contain two normal appearing copies of chromosome 11 and chromosome 11 sequences in a marker chromosome (Jesudasan et al., 1994; Macville et al., 1999) . While the marker in D98/ AH-2 is a der(3) chromosome, the marker in CCL2 is a der(11) chromosome. We have previously shown that the der(3) chromosome of D98/AH-2 cells contains an interstitial deletion of 2.3 Mb of chromosome 11q13 sequences (Srivatsan et al., 2000) . FISH with chromosome 11 painting and seven different chromosome 11q13 specific probes; 32D10, 92C11, 41I21, 152L21, 149A4, 188N21, and 129F8 showed the marker Table 1 FISH analysis of cervical tumors using locus-specific probes from the chromosomal region 11q13 Figure 6 ). While two copies of probes 32D10, 188N21 and 129F8 were localized to the distal end of one arm of the marker chromosome, probes 92C11, 41I21, 152L21 and 149A4 hybridized to both arms of the marker chromosome. One of the hybridizations was near the centromere and the other hybridization was in the other arm of the chromosome, at the site of 32D10, 188N21 and 129F8. Representative data for the hybridization to 92C11, 129F8 probes and for the dual color hybridization to 152L21 and 188N21 probes are shown in Figure 6b -d. Unlike D98/AH-2, in which probes 41I21, 92C11, 149A4 and 152L21 are deleted from the der(3) chromosome (green horizontal bars in Figure 1 ), these probes are retained in the der(11) marker chromosome of CCL2 cells. Differences in the chromosome 11q13 make up of the marker chromosomes raised the possibility that the HeLa sub lines may not be clonal in origin. To answer this question, PCR was performed on the different HeLa cell isolates using the microsatellite and STS markers localized between PYGM and INT2 ( Figure  1a ). Homozygous deletion of D11S913 sequences was observed in D98/AH-2, CCL2, and five other HeLa cell isolates (Figure 7a ). Thus, we observed loss of 11q13 sequences from both the normal appearing copies of chromosome 11 and from the derivative marker chromosomes of the HeLa cell isolates thereby confirming the clonality of the various HeLa sub lines.
Precise mapping of this homozygous deletion was carried out using overlapping primers designed from the 152L21 BAC genome. BAC and placental DNAs were used as controls. Absence of a PCR product was seen for a number of PCR pairs in all seven HeLa cell isolates confirming homozygous deletion of chromosome 11q13 sequences ( Table 2 ). The proximal (centromeric) and distal (telomeric) breakpoints of deletion were localized to a 5.7 kb interval between EST AW167735 and EST F05086 sequences ( Figure  7a ). Mapping of homozygous deletion to the 5.7 kb interval was confirmed by Southern blotting using genomic probes spanning the region of deletion (data not shown). Figure 5 Homozygous deletion of D11S913 sequences in a primary tumor. PCR product for the D11S913 marker (220-bp) is absent in tumor 12. This sample however yields products for 152L21 SP6 (82-bp) and 152L21 T7 (90-bp) genomic sequences, localizing the deletion to a 75 kb interval. The homozygous deletion was confirmed by three independent PCR reactions To determine whether 11q13 sequence deletions played a role in the re-expression of tumorigenicity, the non-tumorigenic and tumorigenic HeLa X GM0077 hybrids were studied using the 11q13 probes. PCR showed homozygous deletion of D11S913 sequences in the tumorigenic hybrid cell lines CGL4 and 1-1-4TR (Figure 7b ). Deletion breakpoints were again localized to the interval between EST AW167735 and EST F05086.
Southern blot analysis has also shown presence of a normal and a rearranged copy of D11S913 sequences in two normal fibroblasts, GM0077 and GM0468 (data not shown). The rearranged size was identical to that of HeLa cells indicating hemizygous deletion in these two fibroblasts. Presence of this hemizygous deletion was confirmed by a semi-quantitative PCR using probes localized within and out side of deletion. A comparison of the PCR product intensities in these two samples to those of other fibroblasts (non-deleted by Southern blots) showed reduced intensity for the deleted sequences in GM0077 and GM0468 ( Figure  7c ). The data further demonstrated that the HeLa cell derived non-tumorigenic hybrid CGL1, contained one normal copy of chromosome 11, which was sufficient for the suppression of tumorigenicity in nude mice (Figure 7c) . Loss of 11q13 sequences from this normal chromosome 11 resulted in the re-expression of tumorigenicity.
Absence of MEN1 gene mutation in primary tumors
Since, we have previously shown that 11q13 deletions in cervical cancer cell lines did not involve the MEN1 gene (Srivatsan et al., 2000) , we wanted to determine whether the MEN1 gene was mutated in primary tumors. SSCP analysis was performed for all nine coding exons of the gene . Two gastrinoma samples, which have previously been shown to contain mutations (one for exon 2 and the other for exon 4), were used as positive controls for the detection of band shift in SSCP gels. We did not detect abnormal bands for any of the nine exons in the cervical tumors (data not shown). The results indicated that chromosome 11q13 deletions in cervical tumors represented the unmasking of yet another putative tumor suppressor gene at 11q13.
Discussion
Previous LOH studies have shown deletion of 11q sequences in cervical tumors (Srivatsan et al., 1991; Figure 6 FISH analysis of the HeLa cell line, CCL2. (a) Whole chromosome 11 painting reveals the presence of two normal appearing copies of chromosome 11 and a der(11) chromosome involving complex rearrangement of chromosome 11 sequences; (b) Cosmid 92C11 hybridizes to 11q13 locus in normal copies of chromosome 11 and to both arms of the der(11) marker chromosome; (c) Cosmid 129F8 hybridizes to the normal appearing copies of chromosome 11 and to only one arm of the marker chromosome. Also, two copies of this probe are observed on the marker chromosome; (d) A dual color FISH with 152L21 (green) and 188N21 (red) shows hybridization of both probe sequences to the two normal appearing copies of chromosome 11 and to the marker chromosome 11. While probe 188N21 (red) is present only on one arm of the marker chromosome, probe 152L21 (green signal) is visualized on both arms of the marker chromosome. FISH data thus reveals participation of 11q13 sequences in chromosome 11 rearrangements in CCL2 (HeLa) cells. Arrows point to der(11) marker chromosome Mitra et al., 1994; Mullokandov et al., 1996) . Microsatellite analysis, using chromosome 11 specific markers, has localized a putative tumor suppressor gene to 11q22-24 (Hampton et al., 1994) . Recently, Pulido et al. (2000) have narrowed this gene to a 6 cM interval at 11q23.1-23.2. The markers used in their studies were predominantly from 11q22-24. However, four 11q13 probes used have identified interstitial deletions at 11q13. Additionally, the 11q23 markers with the highest frequency of allelic loss reported by Hampton et al. (1994) were absent in the t(X;11) chromosome conferring tumor suppression in the HeLa cells (Misra and Srivatsan, 1989) . Thus the results suggested the presence of yet another putative tumor suppressor gene at 11q, proximal to 11q22, in cervical cancer. Investigation of cervical cancer cell lines has shown rearrangement of 11q13 as a frequent event in cervical cancer (Jesudasan et al., 1994 (Jesudasan et al., , 1995 . We therefore evaluated the status of 11q13 in primary tumors.
We report here that the deletion of 11q13 sequences occurs at a significant frequency (47%) in cervical cancer. Identification of deletion by FISH at the D11S913 locus in two tumors that were negative by the microsatellite analysis, further, suggested that the deletion frequency reported here is an under estimate. Although three different regions were lost, nine of the tumors had allelic loss at D11S913 locus. Minimal deletion at this site was localized to a 300 kb interval between D11S4908 and D11S5023. A study incorporating both FISH and microsatellite markers might not only be valuable for the precise determination of the deletion frequency, but also will be helpful in the fine mapping analysis of the deletion. Additionally, microsatellite studies on normal epithelial, dysplatic, and CINs (carcinoma in situ) purified from the microdissected tumor samples should be helpful in determining the clinical significance of chromosome 11q13 deletion in cervical cancer.
The minimal 300 kb deletion encompasses the homozygous deletion in HeLa cells and in a primary tumor. We have not observed homozygous deletion in any of the normal non-tumorigenic samples indicating homozygous deletion as a tumor related event. Although the putative cervical cancer tumor suppressor gene may be localized anywhere within the 300 kb sequence, it is also likely that the gene may be localized near the region of homozygous deletion.
Chromosome 11q13 harbors oncogenes cyclin D1, HST1 (fgf4) and INT2 (fgf3). Amplification of this genomic region is observed in a number of human tumors (Shuster et al., 2000) . It has been suggested that the fragile sites form boundaries of genomic amplifications (Coquelle et al., 1997; Shuster et al., 2000) . A breakage-fusion-bridge mechanism of amplification at 11q13 possibly involves breaks at proximal 11q13 (FRA11A) and at INT2 (FRA11H) (Shuster et al., 2000) . We speculate therefore that the allelic imbalance at the INT2 locus in some of the primary tumors was preceded by a deletion at D11S913. The best example is the HeLa sub lines where the derivative marker chromosomes show translocation and duplication of INT2 to be associated with a deletion at D11S913. Although not detected by microsatellite probes, FISH shows D11S913 deletions in additional tumors (tumors 3 and 6) indicating a significant frequency of deletion at this site. Further, Perucca-Lostanlen et al. (1997) have mapped the FRA11A to the interval between D11S913 and ACTN3 and the Human Genome database maps this interval to a 500 kb sequence. Since, we have observed identical homozygous deletion of D11S913 site in HeLa cells and tumorigenic hybrids PCR analysis of HeLa X GM0077 hybrid cell lines reveals the absence of D11S913 sequences in the tumorigenic hybrid cell lines CGL4 and 1-1-4TR. Both the HeLa cells and the hybrids contain PCR products for EST AW167735 (117-bp) and EST F05086L (305-bp) sequences thereby mapping the homozygous deletion to a 5.7 kb interval of chromosome 11q13; (c) A semi-quantitative PCR, performed in the same reaction tube, using a probe within (contig 282789-251 bp, mapped 2.2 kb proximal to D11S913) and outside (CA54481-152 bp, mapped 6.1 kb proximal to D11S913) of HeLa cell deletion shows hemizygous loss of D11S913 site in normal fibroblasts GM0077 and GM0468. Reduced intensity of contig 282789 sequences observed in the non-tumorigenic CGL1 cells suggests existence of a single copy of GM0077 in this cell line. Fibroblasts GM0023 and GM5399 were used as controls. Numbers at the bottom refer to intensity ratios and hemizygous deletion of the same sequences in two different fibroblasts, we hypothesize that the sequences at D11S913 might represent sequences of FRA11A.
Besides cervical cancer, LOH studies have implicated chromosome 11q13 in a number of human tumors including breast, head and neck, neuroblastoma and endocrine tumors (Srivatsan et al., 1993; Zhuang et al., 1995; Chakrabarti et al., 1998; Venugopalan et al., 1998; Tanaka et al., 1998) . Recently, the minimal 11q13 deletion for a nasopharyngeal carcinoma tumor suppressor gene was localized to a 1.8 Mb interval that overlapped with the 300 kb deletion observed in cervical cancer (Cheng et al., 2002) . Thus, it is an interesting possibility that a single putative tumor suppressor at 11q13 might be involved in the development of different human tumors.
Endocrine tumor studies have resulted in the isolation of the MEN1 gene localized to 11q13 . While this gene is mutated in greater than 90% of familial MEN1 tumors, mutation is restricted to less than 55% of the sporadic tumors. There are also reports on sporadic pituitary tumors and sporadic pancreatic endocrine tumors that have 11q13 deletions without MEN1 gene mutations (Prezant et al., 1998; Wang et al., 1998; Tanaka et al., 1998) . Finally, in the present investigation, we did not observe MEN1 gene mutations in cervical tumors containing 11q13 deletions. Although, other mechanisms such as methylation or mutation of the promoter or non-coding sequences might play a role in the inactivation of the MEN1 gene, the results suggest the possible existence of a second putative tumor suppressor gene at 11q13.
The Human Genome database search of the 300 kb minimal deletion maps at least six different genes; BCRP1 (breakpoint cluster region protein1), SART1 (Squamous cell carcinoma antigen recognized by T cells), CATSPER1 (Cation channel of sperm), GAL3ST2 (beta-galactosidase-3-O-sulfotransferase 3), SAP145 (spliceosome associated protein145), and PACS1 (protein associated with cytosolic sorter1). SAP145 and PACS1 are localized within 100 kb -CAA GAC CTA TAT ATT TTG CTT TAG-3'  371  Present  Present  5'-TCA CAC CCA GCA TTT ATA ATT ACC TGG-3'  282789 3  5'-GGG CTT AAA GGA TCC TCC TG-3'  736  Present  Present  5'-TAG GTC TTG CCT TGA GGT GG- proximal (centromeric) to homozygous deletion. Three other genes localized outside of minimal deletion but in the vicinity, BRMS1 (breast cancer metastasis suppressor1), RIN1 (ras inhibitor1), RAB1B (ras associated binding protein 1B) are mapped 115 -170 kb distal (telomeric) to deletion. Mutation analysis of these genes should reveal whether any of the genes are involved in the development of cervical cancer.
The possibility exists that 11q13 deletion may not represent inactivation of a putative tumor suppressor gene, but genomic instability of the 11q13 fragile site. This could be similar to the deletion of 3p14 observed in various human tumors. FHIT (fragile histidine triad) gene localized to 3p14.2 is reported to be a tumor suppressor gene. Exon specific deletions and absence of transcripts in tumors qualify FHIT as a tumor suppressor gene (Ohta et al., 1996; Sozzi et al., 1997; Greenspan et al., 1997) . Further, tumor suppression resulting from the transfer of the gene into tumor cell lines also suggests that FHIT is a tumor suppressor gene (Siprashvili et al., 1997; Ramesh et al., 2001; Ishii et al., 2001) . However, observation of FHIT gene deletions in normal tissues, absence of point mutations and presence of normal FHIT transcripts in tumors suggests that FHIT may not be a tumor suppressor gene (Panagopoulos et al., 1997; Mao, 1998) . Thus, Boldog et al. (1997) have suggested that the genomic instability at FRA 3B is most likely responsible for chromosome 3p14 deletions including the inactivation of the FHIT gene. Similarly, it has been proposed that the fragility of the FRA16D may be responsible for deletions at 16q23 in tumors and for the inactivation of the WWOX/FOR (FRA 16D oxido reductase) gene at this site (Ried et al., 2000; Bednarek et al., 2001 , Richard, 2001 ).
In conclusion, we have shown that chromosome 11q13 deletion occurs to a significant frequency in cervical cancer. We have confirmed the deletion by the FISH analysis using locus specific probes. We have localized this deletion to a 300 kb interval between D11S4908 and D11S5023. We have also shown that homozygous deletion of 11q13 sequences within this minimal deletion is observed in a primary tumor, in HeLa cells and in HeLa cell derived hybrids. It is therefore likely that the putative tumor suppressor gene might be localized to a smaller interval, to the region of the homozygous deletion. Thus, the identification of sequences inactivated in the HeLa cells and the tumorigenic hybrids might be valuable for the cloning of the putative cervical cancer tumor suppressor gene.
Materials and methods
Tumor samples
Following Institutional Review Board (IRB) guidelines, cervical tumors were chosen for the study. Tissues from the tumor and the benign endometrium (constitutional cells) were obtained at the time of hysterectomy and were frozen at 7708C. DNA extraction was performed as described (Monk et al., 1994) .
Cell lines
The fibroblast cell line GM0077, the HeLa cell lines D98/AH-2, CCL2 and HeLa Stone mass, their clonal derivatives D98/ AH2-S, CCL2.1, CCL2.2, HeLa Stone clone C6; and the HeLa cell derived non-tumorigenic and tumorigenic hybrids were all grown in MEM medium supplemented with 10% FCS. High molecular weight genomic DNA was isolated from the cell lines as previously described (Jesudasan et al., 1995) .
Centromere, cosmid and BAC probes
Isolation and purification of BAC and cosmid probes have all been described (Srivatsan et al., 2000) . Cosmid probes 10B11, 25G9, 32D10/88G7, 92C11, 102C11, 129F8, and 149A4-representing MEN1, INT2, PYGM, D11S4907/4908, D11S546, cyclin D1 and 776E2R loci respectively were isolated from the Los Alamos chromosome 11 cosmid library. Screening of the human BAC library (Research Genetics, Alabama, USA) with FAU, D11S449, D11S913 and GSTP1 probes resulted in the isolation of BACs 184C17, 57D24, 41I21/152L21 and 188N21 respectively. Genomic sequences for the T7 and SP6 ends of BACs 41I21 and 152L21 were determined from the BAC end clones using the established protocol . Restriction mapping of the BAC DNAs was performed on partial restriction fragments using the pulsed field gel electrophoretic (PFGE) analysis (Jesudasan et al., 1995) .
Polymerase chain reaction (PCR)
Primers for the various microsatellite and RFLP markers used in the present investigation were synthesized as described (Chakrabarti et al., 1998; Venugopalan et al., 1998) . Primers for microsatellite markers D11S5021, D11S5022, D11S5023 and D11S5024 were derived from the genomic sequences of BACs 41I21 and 152L21. Microsatellite markers (CA) 23 and CTTT were designed from the genomic sequences of INT 2 containing cosmid 31A9. PCR amplification was performed in a 25-ml-reaction volume with 100 ng of genomic DNA. Cycling conditions and annealing temperatures followed the published protocol (Chakrabarti et al., 1998) . For the RFLP probes, Cyclin D1, INT2 and D11S533, the PCR products were analysed with or without restriction enzyme digestion and the fragments analysed on 7% PAGE gels. Allelic loss was determined by the loss of a polymorphic allele in the tumor lanes of the ethidium bromide stained gels.
PCR products obtained by the microsatellite markers were denatured at 948C and analysed on 6% acrylamide/7 M-urea gels (Pharmacia Biotech, Piscataway, NJ, USA). The gels were electrophoresed on the A.L.F. DNA sequencer (Pharmacia) at a fixed power of 45 W for 4 h. A fluorescein-labeled 50-base-pair ladder (Pharmacia) was run in a separate lane as an external size standard. Alleles were identified visually and allelic size and intensities were determined using the Fragment Manager Program. LOH was scored by the loss of a polymorphic allele in the tumor samples and a loss of at least 30% was scored as an allelic loss as described (Chakrabarti et al., 1998) .
Fluorescence in situ hybridization (FISH)
Biotin-16-dUTP labeled chromosome 11 centromere (asatellite) and digoxigenin -11-dUTP labeled INT2 probes were obtained from Oncor, Gaithersburg, MD, USA. Labeling of all other BAC and cosmid probes and hybridization of the probes to metaphase/interphase spreads were performed as previously described (Jesudasan et al., 1995; Zhuang et al., 1997) .
Post-hybridization washes were performed thrice in 50% formamide/26SSC, and twice in 16SSC and 0.16SSC. Each wash was for 5 min at 458C. The biotin-labeled DNA was visualized with 5 mg/ml fluorescein-isothiocyanate (FITC; Vector Laboratories, Burlingame, CA, USA) conjugated to avidin and the digoxigenin-labeled control DNA with 2 mg/ ml anti-digoxigenin Fab fragments conjugated to rhodamine (Boehringer Mannheim). Interphase nuclei were counterstained with 4,6-diamidino 2-phenylindole (DAPI) in Vectashield solution (Vector). At least 100 nuclei were counted per slide. Presence of one copy of the cosmid or BAC hybridization signal in more than 15% of cells in tumors having two centromeric copies were scored as allelic deletions. Presence of one or two probe signals with three copies of the centromere (trisomy of chromosome 11) was also considered a deletion.
Digital image analysis
A digital acquisition of gray scale images were captured using Photometrics CCD camera SenSys (Photometrics, LTD, Tucson, AZ, USA), interfaced to a Power PC 1800 computer and mounted on the Zeiss Axiophot-2 epifluorescence microscope. Images were acquired using filters specific for DAPI, fluorescein and rhodamine (TR1, TR2, and TR3; Chroma Technologies, Brattleboro, VT, USA) and the IP Lab image software (Scan Analytics Corporation, Vienna, VA, USA).
Single strand conformational polymorphism (SSCP)
PCR amplification of the normal and tumor DNAs with the primers for the nine coding exons of the MEN-1 gene were performed as described (Wang et al., 1998) .
